RTI uses cookies to offer you the best experience online. By clicking “accept” on this website, you opt in and you agree to the use of cookies. If you would like to know more about how RTI uses cookies and how to manage them please view our Privacy Policy here. You can “opt out” or change your mind by visiting: http://optout.aboutads.info/. Click “accept” to agree.
A validated liquid chromatography tandem mass spectrometry method for quantification of erlotinib, OSI-420 and didesmethyl erlotinib and semi-quantification of erlotinib metabolites in human plasma
Svedberg, A., Gréen, H., Vikström, A., Lundeberg, J., & Vikingsson, S. (2015). A validated liquid chromatography tandem mass spectrometry method for quantification of erlotinib, OSI-420 and didesmethyl erlotinib and semi-quantification of erlotinib metabolites in human plasma. Journal of Pharmaceutical and Biomedical Analysis, 107, 186-195. https://doi.org/10.1016/j.jpba.2014.12.022
A liquid chromatography tandem mass spectrometry method was developed and validated for quantification of erlotinib and its metabolites in human plasma. The method is suitable for therapeutic drug monitoring and pharmacokinetic studies.The substances were extracted using protein precipitation, separated on a BEH XBridge C18 column (100. ×. 2.1. mm, 1.7. μm) by gradient elution at 0.7. mL/min of acetonitrile and 5. mM ammonium acetate. The concentration was determined using a Waters Xevo triple quadrupole mass spectrometer in a multi reaction monitoring mode. The total run time was 7. min. Deuterated erlotinib and OSI-597 were used as internal standard for erlotinib and its metabolites, respectively.Erlotinib, OSI-420 and didesmethyl erlotinib were quantified in the concentration range 25-5000. ng/mL, 0.5-500. ng/mL and 0.15-10. ng/mL, respectively. Precision and accuracy was
